Who we are
Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207
About Biosimilars:
Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of approximately USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. Global sales of biosimilars are estimated to exceed $15 billion by 2020. By 2030, analysts estimate that this figure could rise to over $60 billion.
Contact:
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg
Germany
phone +49 (0) 89 - 86 46 67 100
fax + 49 (0) 89 - 86 46 67 110
info@formycon.com
Company Details
- Employees
- 194
- Founded
- -
- Address
- Fraunhoferstrasse 15, Planegg,by 82152,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- formycon.com
- Keywords
- Ophthalmology, Immunology, Scientific Professionals, Biosimilar Medicines, Drug Product, CMC with strong Analytics, Device Development, Preclinical & Bioanalytics, CMC Regulatory Affairs, Project Management, Quality Management, Certified GMP Analytical Laboratory, Biosimilar Development, Anti Body Based COVID-19 Drugs.
- HQ
- Planegg, BY
Formycon Ag Questions
Formycon Ag's website is formycon.com
Formycon Ag's LinkedIn profile is https://de.linkedin.com/company/formycon
Formycon Ag has
194 employees.
View email and phone details for 194
employees at Formycon Ag.
Formycon Ag's industry is
Biotechnology Research
Formycon Ag's top competitors are
Immatics,
Coriolis Pharma,
Immunic Therapeutics,
Medigene Ag,
Morphosys,
Leukocare Ag,
Proteros Biostructures Gmbh,
Eisbach Bio Gmbh,
Tubulis Gmbh,
Iomx Therapeutics Ag.
Formycon Ag's categories are Biotechnology Research
Formycon Ag's founding year is 2012
